Ceramide induces the apoptosis of non‑small cell lung cancer cells through the Txnip/Trx1 complex

Int J Mol Med. 2021 May;47(5):85. doi: 10.3892/ijmm.2021.4918. Epub 2021 Mar 24.

Abstract

Ceramide is a biologically active sphingomyelin that inhibits cell growth and proliferation. In previous studies, it was demonstrated that the use of lipopolysaccharides induces acid sphingomyelinases to produce ceramide, promoting lung cancer cell apoptosis; however, the specific mechanisms of this action remain unclear. Thioredoxin‑interacting protein (Txnip) plays an important role in the signal transmission of redox reactions inside and outside the cell. Thus, it was hypothesized that ceramide induces apoptosis in lung adenocarcinoma cells (A549 and PC9) by modulating the Txnip/Trx1 complex. In the present study, the Cell Counting kit‑8 method was used to detect cell activity and the drug concentration. Hoechst 33258 staining and flow cytometry were used to detect cell apoptosis, and the positional association between Txnip and Trx1 upregulated by ceramide was observed by immunofluorescence confocal microscopy. Reverse transcription‑quantitative polymerase chain reaction and western blot analysis were used to detect the changes in related gene, mRNA and protein expression levels. The results revealed that ceramide treatment resulted in the upregulation of Txnip and in the reduction of Trx1 activities. However, the Txnip inhibitor, verapamil, reversed these changes. The analysis of mRNA expression further verified the changes observed in the protein expression of Txnip, Trx1 and apoptosis‑related proteins. On the whole, the present study demonstrates that ceramide induces the apoptosis of lung cancer cells by regulating the Txnip/Trx1 complex.

Keywords: ceramide; apoptosis; lung cancer; Txnip; Trx1; signaling pathway.

MeSH terms

  • Apoptosis / drug effects
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carrier Proteins / genetics
  • Carrier Proteins / metabolism*
  • Caspase 3 / genetics
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Ceramides / pharmacology*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / pathology
  • Multiprotein Complexes
  • Thioredoxins / genetics
  • Thioredoxins / metabolism*
  • Verapamil / pharmacology

Substances

  • Carrier Proteins
  • Ceramides
  • Multiprotein Complexes
  • TXNIP protein, human
  • Thioredoxins
  • Verapamil
  • CASP3 protein, human
  • Caspase 3

Grants and funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81400058) and the Anhui Province Science and Technology Tackling Plan Project (no. 1401045016).